|
18/09/2024
|
13:20
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
17/09/2024
|
07:00
|
Japan Filing Acceptance: Blenrep Multiple Myeloma
|
RNS
|
|
13/09/2024
|
07:00
|
China Breakthrough Therapy Designation for Blenrep
|
RNS
|
|
12/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
12/09/2024
|
07:00
|
Positive mRNA flu vaccine Phase II headline data
|
RNS
|
|
11/09/2024
|
17:27
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
11/09/2024
|
15:30
|
Change of Registered Office
|
RNS
|
|
11/09/2024
|
07:00
|
Update on phase I/II therapeutic HSV vaccine trial
|
RNS
|
|
09/09/2024
|
14:30
|
Depemokimab late-breaking data presented at ERS
|
RNS
|
|
06/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
06/09/2024
|
07:00
|
Positive Phase III results for Nucala in COPD
|
RNS
|
|
02/09/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
29/08/2024
|
07:00
|
EMA approval on Arexvy for 50-59 at risk
|
RNS
|
|
28/08/2024
|
07:10
|
SENKU Designation for Bepirovirsen in Japan
|
RNS
|
|
28/08/2024
|
07:05
|
Nucala approved in Japan for use in CRSwNP
|
RNS
|
|
28/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
21/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
20/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
20/08/2024
|
07:00
|
B7-H3 ADC US FDA Breakthrough Therapy Designation
|
RNS
|
|
16/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
12/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
06/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
02/08/2024
|
07:00
|
FDA Expands Jemperli Approval
|
RNS
|
|
01/08/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
31/07/2024
|
07:00
|
2nd Quarter Results
|
RNS
|
|
29/07/2024
|
08:18
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
29/07/2024
|
07:00
|
CHMP positive opinion on Arexvy for 50-59 at risk
|
RNS
|
|
19/07/2024
|
10:36
|
Blenrep EMA Filing Acceptance
|
RNS
|
|
18/07/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
16/07/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
15/07/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
12/07/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
03/07/2024
|
07:00
|
GSK and CureVac collaboration restructured
|
RNS
|
|
01/07/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
28/06/2024
|
17:37
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
24/06/2024
|
07:05
|
Omjjara approved in Japan for myelofibrosis
|
RNS
|
|
24/06/2024
|
07:00
|
EMA validates Jemperli marketing authorisation
|
RNS
|
|
21/06/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
12/06/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
11/06/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
10/06/2024
|
18:27
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
10/06/2024
|
07:00
|
FDA approves Arexvy for adults 50-59 at risk
|
RNS
|
|
03/06/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
03/06/2024
|
13:03
|
Unprecedented results in Jemperli trial continue
|
RNS
|
|
03/06/2024
|
07:05
|
ASCO positive Blenrep DREAMM-8 trial results
|
RNS
|
|
03/06/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
24/05/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
21/05/2024
|
07:00
|
Positive phase III asthma results for depemokimab
|
RNS
|
|
20/05/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
17/05/2024
|
07:00
|
GSK completes sale of shares in Haleon plc
|
RNS
|